Fiscal Cliff Legislation Adjusts ESRD Payment Bundle To Help Offset Doc Fix
This article was originally published in The Pink Sheet Daily
Executive Summary
In legislation passed by both chambers of Congress Jan. 1, the cost of a one-year reprieve from sharp cuts to Medicare physician payments, scheduled to begin in 2013, would be offset by a reduction in Medicare’s bundled payment for end-stage renal disease. The reduced payment would take into account a drop in the use of erythropoiesis-stimulating agents observed over the last several years.
You may also be interested in...
Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
Reimbursement Briefs: ESRD Drugs, Medicare Data, Rx Adherence, Cancer Drug Value
Physician patch bill delays including oral ESRD drugs in bundled Medicare payments until 2024; ASCO working on method to score relative value of cancer drugs, and more news in brief.
Epogen Use Re-Calculation Drives 9.4% Medicare ESRD Bundled Payment Cut In 2014
CMS was directed by the American Taxpayer Relief Act to “rebase” the ESRD payment level by re-calculating the use of erythropoiesis-stimulating agents and other infused or injectable therapies.